Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.

Göthert JR, Imsak R, Möllmann M, Kesper S, Göbel M, Dührsen U, Scholz A, Lücking U, Baumann M, Unger A, Schultz-Fademrecht C, Klebl B, Eickhoff J, Choidas A, Dürig J.

Oncotarget. 2018 May 29;9(41):26353-26369. doi: 10.18632/oncotarget.25293. eCollection 2018 May 29.

2.

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE.

J Clin Oncol. 2018 Jun 1:JCO2017768960. doi: 10.1200/JCO.2017.76.8960. [Epub ahead of print]

PMID:
29856692
3.

Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.

Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial Investigators.

J Clin Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11.

PMID:
29750632
4.

Light chain monoclonal gammopathy of undetermined significance is characterized by a high disappearance rate and low risk of progression on longitudinal analysis.

Pelzer BW, Arendt M, Moebus S, Eisele L, Jöckel KH, Dührsen U, Dürig J; Heinz Nixdorf Recall Study Investigative Group.

Ann Hematol. 2018 Aug;97(8):1463-1469. doi: 10.1007/s00277-018-3305-x. Epub 2018 Apr 9.

PMID:
29629484
5.

SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.

Johansson P, Klein-Hitpass L, Choidas A, Habenberger P, Mahboubi B, Kim B, Bergmann A, Scholtysik R, Brauser M, Lollies A, Siebert R, Zenz T, Dührsen U, Küppers R, Dürig J.

Blood Cancer J. 2018 Jan 19;8(1):11. doi: 10.1038/s41408-017-0036-5.

6.

Successful treatment of cerebral aspergillosis: case report of a patient with T-cell large granular lymphocytic leukemia (T-LGL).

Turki AT, Rashidi-Alavijeh J, Dürig J, Gerken G, Rath PM, Witzke O.

BMC Infect Dis. 2017 Dec 28;17(1):797. doi: 10.1186/s12879-017-2877-8.

7.

Biased IGH VDJ gene repertoire and clonal expansions in B cells of chronically hepatitis C virus-infected individuals.

Tucci FA, Kitanovski S, Johansson P, Klein-Hitpass L, Kahraman A, Dürig J, Hoffmann D, Küppers R.

Blood. 2018 Feb 1;131(5):546-557. doi: 10.1182/blood-2017-09-805762. Epub 2017 Dec 14.

PMID:
29242186
8.

Drug-perturbation-based stratification of blood cancer.

Dietrich S, Oleś M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hüllein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oleś AK, Słabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Dürig J, Ringshausen I, Zapatka M, Huber W, Zenz T.

J Clin Invest. 2018 Jan 2;128(1):427-445. doi: 10.1172/JCI93801. Epub 2017 Dec 11.

9.

Inhibitors of the Diadenosine Tetraphosphate Phosphorylase Rv2613c of Mycobacterium tuberculosis.

Götz KH, Hacker SM, Mayer D, Dürig JN, Stenger S, Marx A.

ACS Chem Biol. 2017 Oct 20;12(10):2682-2689. doi: 10.1021/acschembio.7b00653. Epub 2017 Sep 26.

PMID:
28892605
10.

Is long-term particulate matter and nitrogen dioxide air pollution associated with incident monoclonal gammopathy of undetermined significance (MGUS)? An analysis of the Heinz Nixdorf Recall study.

Orban E, Arendt M, Hennig F, Lucht S, Eisele L, Jakobs H, Dürig J, Hoffmann B, Jöckel KH, Moebus S.

Environ Int. 2017 Nov;108:237-245. doi: 10.1016/j.envint.2017.08.007. Epub 2017 Sep 5.

PMID:
28886417
11.

Tumor-derived exosomes modulate PD-L1 expression in monocytes.

Haderk F, Schulz R, Iskar M, Cid LL, Worst T, Willmund KV, Schulz A, Warnken U, Seiler J, Benner A, Nessling M, Zenz T, Göbel M, Dürig J, Diederichs S, Paggetti J, Moussay E, Stilgenbauer S, Zapatka M, Lichter P, Seiffert M.

Sci Immunol. 2017 Jul 28;2(13). pii: eaah5509. doi: 10.1126/sciimmunol.aah5509.

PMID:
28754746
12.

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.

Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Hänel M, Salwender HJ, Weisel K, Dürig J, Görner M, Kirchner H, Peter N, Graeven U, Lordick F, Hoffmann M, Reimer P, Blau IW, Jauch A, Dembowsky K, Möhler T, Wuchter P, Goldschmidt H.

Bone Marrow Transplant. 2017 Aug;52(8):1194-1198. doi: 10.1038/bmt.2017.91. Epub 2017 May 15. No abstract available.

13.

HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia.

Wagner B, da Silva Nardi F, Schramm S, Kraemer T, Celik AA, Dürig J, Horn PA, Dührsen U, Nückel H, Rebmann V.

Cancer. 2017 Mar 1;123(5):814-823. doi: 10.1002/cncr.30427. Epub 2016 Nov 2.

14.

Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.

Johansson P, Klein-Hitpass L, Grabellus F, Arnold G, Klapper W, Pförtner R, Dührsen U, Eckstein A, Dürig J, Küppers R.

Oncotarget. 2016 Sep 20;7(38):62627-62639. doi: 10.18632/oncotarget.11548.

15.

Deorphanization and characterization of the ectopically expressed olfactory receptor OR51B5 in myelogenous leukemia cells.

Manteniotis S, Wojcik S, Göthert JR, Dürig J, Dührsen U, Gisselmann G, Hatt H.

Cell Death Discov. 2016 May 9;2:16010. doi: 10.1038/cddiscovery.2016.10. eCollection 2016.

16.

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.

Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, Dürig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D.

Oncotarget. 2016 Aug 11;8(49):84847-84862. doi: 10.18632/oncotarget.11215. eCollection 2017 Oct 17.

17.

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.

Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG; Hx-CD20-407 Study Investigators.

Leuk Lymphoma. 2017 Feb;58(2):348-356. Epub 2016 Jul 7.

PMID:
27389174
18.

A novel LAMB2 gene mutation associated with a severe phenotype in a neonate with Pierson syndrome.

Zemrani B, Cachat F, Bonny O, Giannoni E, Durig J, Fellmann F, Chehade H.

Eur J Med Res. 2016 Apr 30;21:19. doi: 10.1186/s40001-016-0215-z.

19.

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S.

Blood Cancer J. 2016 Mar 11;6:e404. doi: 10.1038/bcj.2016.9.

20.

Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.

López C, Bergmann AK, Paul U, Murga Penas EM, Nagel I, Betts MJ, Johansson P, Ritgen M, Baumann T, Aymerich M, Jayne S, Russell RB, Campo E, Dyer MJ, Dürig J, Siebert R.

Br J Haematol. 2016 Apr;173(2):265-73. doi: 10.1111/bjh.13952. Epub 2016 Feb 25.

PMID:
26917488
21.

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.

Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Dürig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A.

Leuk Lymphoma. 2016;57(6):1291-9. doi: 10.3109/10428194.2015.1128540. Epub 2016 Jan 14.

PMID:
26763349
22.

Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinations.

Stiefelhagen M, Gigel C, Vasyutina E, Möllmann M, Breuer A, Mayer P, Dürig J, Herling M.

Leuk Lymphoma. 2016 Sep;57(9):2235-8. doi: 10.3109/10428194.2015.1135433. Epub 2016 Jan 12. No abstract available.

PMID:
26758550
23.

Anemia and Mild Cognitive Impairment in the German General Population.

Dlugaj M, Winkler A, Weimar C, Dürig J, Broecker-Preuss M, Dragano N, Moebus S, Jöckel KH, Erbel R, Eisele L; Heinz Nixdorf Recall Study Investigative Group.

J Alzheimers Dis. 2016;49(4):1031-42. doi: 10.3233/JAD-150434.

PMID:
26599053
24.

Shorter telomeres correlate with an increase in the number of uniparental disomies in patients with chronic lymphocytic leukemia.

Sellmann L, Scholtysik R, de Beer D, Eisele L, Klein-Hitpass L, Nückel H, Dührsen U, Dürig J, Röth A, Baerlocher GM.

Leuk Lymphoma. 2016;57(3):590-5. doi: 10.3109/10428194.2015.1076929. Epub 2015 Oct 12.

PMID:
26457386
25.

Microwave, r0 Structural Parameters, Conformational Stability, and Vibrational Assignment of (Chloromethyl)fluorosilane.

Guirgis GA, Sawant DK, Brenner RE, Deodhar BS, Seifert NA, Geboes Y, Pate BH, Herrebout WA, Hickman DV, Durig JR.

J Phys Chem A. 2015 Nov 25;119(47):11532-47. doi: 10.1021/acs.jpca.5b06679. Epub 2015 Nov 13.

PMID:
26436757
26.

Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group.

Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M.

Leuk Lymphoma. 2016;57(4):789-96. doi: 10.3109/10428194.2015.1091933. Epub 2015 Oct 13.

PMID:
26377031
27.

Recurrent alterations of TNFAIP3 (A20) in T-cell large granular lymphocytic leukemia.

Johansson P, Bergmann A, Rahmann S, Wohlers I, Scholtysik R, Przekopowitz M, Seifert M, Tschurtschenthaler G, Webersinke G, Jäger U, Siebert R, Klein-Hitpass L, Dührsen U, Dürig J, Küppers R.

Int J Cancer. 2016 Jan 1;138(1):121-4. doi: 10.1002/ijc.29697. Epub 2015 Jul 30.

28.

Molecular spectroscopy and molecular structure - Selected communications presented at the 1st International Turkish Congress on Molecular Spectroscopy (TURCMOS 2013).

Durig JR, Fausto R, Ünsalan O, Bayarı S, Kuş N, Ildız GÖ.

Spectrochim Acta A Mol Biomol Spectrosc. 2016 Jan 5;152:523-4. doi: 10.1016/j.saa.2015.06.085. Epub 2015 Jun 24. No abstract available.

PMID:
26183526
29.

Multipotent Hematopoietic Progenitors Divide Asymmetrically to Create Progenitors of the Lymphomyeloid and Erythromyeloid Lineages.

Görgens A, Ludwig AK, Möllmann M, Krawczyk A, Dürig J, Hanenberg H, Horn PA, Giebel B.

Stem Cell Reports. 2015 Jul 14;5(1):154-155. doi: 10.1016/j.stemcr.2015.06.010. Epub 2015 Jul 14. No abstract available.

30.

R0 Structural parameters, conformational, vibrational studies and ab initio calculations of cyanocyclopentane.

Sawant DK, Klaassen JJ, Gounev TK, Durig JR.

Spectrochim Acta A Mol Biomol Spectrosc. 2015 Dec 5;151:468-79. doi: 10.1016/j.saa.2015.06.116. Epub 2015 Jun 30.

PMID:
26151436
31.

Functional abnormalities and changes in gene expression in fibroblasts and macrophages from the bone marrow of patients with acute myeloid leukemia.

Li Y, Dürig J, Göbel M, Hanoun M, Klein-Hitpaß L, Dührsen U.

Int J Hematol. 2015 Sep;102(3):278-88. doi: 10.1007/s12185-015-1833-x. Epub 2015 Jun 28.

PMID:
26121956
32.

Recurrent CDKN1B (p27) mutations in hairy cell leukemia.

Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Oleś M, Else M, Liu X, Słabicki M, Wu B, Troussard X, Dürig J, Andrulis M, Dearden C, von Kalle C, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel Wahab O, Zenz T.

Blood. 2015 Aug 20;126(8):1005-8. doi: 10.1182/blood-2015-04-643361. Epub 2015 Jun 11.

33.

Microwave, structural, conformational, vibrational studies and ab initio calculations of fluoroacetyl chloride.

Deodhar BS, Brenner RE, Klaassen JJ, Tubergen MJ, Durig JR.

Spectrochim Acta A Mol Biomol Spectrosc. 2015 Sep 5;148:289-98. doi: 10.1016/j.saa.2015.04.007. Epub 2015 Apr 9.

PMID:
25909903
34.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H.

Leukemia. 2015 Aug;29(8):1721-9. doi: 10.1038/leu.2015.80. Epub 2015 Mar 19.

PMID:
25787915
35.

Multipotent hematopoietic progenitors divide asymmetrically to create progenitors of the lymphomyeloid and erythromyeloid lineages.

Görgens A, Ludwig AK, Möllmann M, Krawczyk A, Dürig J, Hanenberg H, Horn PA, Giebel B.

Stem Cell Reports. 2014 Dec 9;3(6):1058-72. doi: 10.1016/j.stemcr.2014.09.016. Epub 2014 Oct 23. Erratum in: Stem Cell Reports. 2015 Jul 14;5(1):154-5.

36.

Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.

Langerbeins P, Busch R, Anheier N, Dürig J, Bergmann M, Goebeler ME, Hurtz HJ, Stauch MB, Stilgenbauer S, Döhner H, Fink AM, Cramer P, Fischer K, Wendtner CM, Hallek M, Eichhorst B.

Am J Hematol. 2014 Dec;89(12):E239-43. doi: 10.1002/ajh.23841. Epub 2014 Sep 26.

37.

Ben van der Veken honor issue.

Durig J.

Spectrochim Acta A Mol Biomol Spectrosc. 2015 Feb 5;136 Pt A:1-2. doi: 10.1016/j.saa.2014.07.019. Epub 2014 Jul 14. No abstract available.

PMID:
25085211
38.

Conformational stability, r(0) structural parameters, vibrational assignments and ab initio calculations of ethyldichlorophosphine.

Darkhalil ID, Paquet C, Waqas M, Gounev TK, Durig JR.

Spectrochim Acta A Mol Biomol Spectrosc. 2015 Feb 5;136 Pt A:42-50. doi: 10.1016/j.saa.2014.01.039. Epub 2014 Jan 24.

PMID:
24618201
39.

Microwave, structural, conformational, vibrational studies and ab initio calculations of isocyanocyclopentane.

Durig JR, Klaassen JJ, Sawant DK, Deodhar BS, Panikar SS, Gurusinghe RM, Darkhalil ID, Tubergen MJ.

Spectrochim Acta A Mol Biomol Spectrosc. 2015 Feb 5;136 Pt A:3-15. doi: 10.1016/j.saa.2013.12.078. Epub 2013 Dec 28.

PMID:
24480667
40.

Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.

Bergmann AK, Schneppenheim S, Seifert M, Betts MJ, Haake A, Lopez C, Maria Murga Penas E, Vater I, Jayne S, Dyer MJ, Schrappe M, Dührsen U, Ammerpohl O, Russell RB, Küppers R, Dürig J, Siebert R.

Genes Chromosomes Cancer. 2014 Apr;53(4):309-16. doi: 10.1002/gcc.22141. Epub 2014 Jan 21.

PMID:
24446122
41.

Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype.

Göthert JR, Eisele L, Klein-Hitpass L, Weber S, Zesewitz ML, Sellmann L, Röth A, Pircher H, Dührsen U, Dürig J.

Cancer Immunol Immunother. 2013 Nov;62(11):1697-1709.

PMID:
24022692
42.

Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia.

Göbel M, Eisele L, Möllmann M, Hüttmann A, Johansson P, Scholtysik R, Bergmann M, Busch R, Döhner H, Hallek M, Seiler T, Stilgenbauer S, Klein-Hitpass L, Dührsen U, Dürig J.

PLoS One. 2013 Aug 23;8(8):e72107. doi: 10.1371/journal.pone.0072107. eCollection 2013.

43.

Microwave and infrared spectra, adjusted r0 structural parameters, conformational stabilities, vibrational assignments, and theoretical calculations of cyclobutylcarboxylic acid chloride.

Klaassen JJ, Darkhalil ID, Deodhar BS, Gounev TK, Gurusinghe RM, Tubergen MJ, Groner P, Durig JR.

J Phys Chem A. 2013 Aug 1;117(30):6508-24. doi: 10.1021/jp404510n. Epub 2013 Jul 15.

PMID:
23777483
44.

Revision of the human hematopoietic tree: granulocyte subtypes derive from distinct hematopoietic lineages.

Görgens A, Radtke S, Möllmann M, Cross M, Dürig J, Horn PA, Giebel B.

Cell Rep. 2013 May 30;3(5):1539-52. doi: 10.1016/j.celrep.2013.04.025. Epub 2013 May 23.

45.

CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia.

Fedorchenko O, Stiefelhagen M, Peer-Zada AA, Barthel R, Mayer P, Eckei L, Breuer A, Crispatzu G, Rosen N, Landwehr T, Lilienthal N, Möllmann M, Montesinos-Rongen M, Heukamp L, Dürig J, Hallek M, Fingerle-Rowson G, Herling M.

Blood. 2013 May 16;121(20):4126-36. doi: 10.1182/blood-2012-11-466250. Epub 2013 Apr 1.

46.

Prevalence and incidence of anemia in the German Heinz Nixdorf Recall Study.

Eisele L, Dürig J, Broecker-Preuss M, Dührsen U, Bokhof B, Erbel R, Moebus S, Jöckel KH; Heinz Nixdorf Recall Study Investigative Group.

Ann Hematol. 2013 Jun;92(6):731-7. doi: 10.1007/s00277-013-1697-1. Epub 2013 Feb 21.

PMID:
23430088
47.

Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.

Lutzny G, Kocher T, Schmidt-Supprian M, Rudelius M, Klein-Hitpass L, Finch AJ, Dürig J, Wagner M, Haferlach C, Kohlmann A, Schnittger S, Seifert M, Wanninger S, Zaborsky N, Oostendorp R, Ruland J, Leitges M, Kuhnt T, Schäfer Y, Lampl B, Peschel C, Egle A, Ringshausen I.

Cancer Cell. 2013 Jan 14;23(1):77-92. doi: 10.1016/j.ccr.2012.12.003.

48.

Raman and infrared spectra, r₀ structural parameters, and vibrational assignments of (CH₃)₂PX where X=H, CN, and Cl.

Panikar SS, Deodhar BS, Sawant DK, Klaassen JJ, Deng J, Durig JR.

Spectrochim Acta A Mol Biomol Spectrosc. 2013 Feb 15;103:205-15. doi: 10.1016/j.saa.2012.10.032. Epub 2012 Nov 23.

PMID:
23261615
49.

Cellular origin and pathophysiology of chronic lymphocytic leukemia.

Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Dürig J, Küppers R.

J Exp Med. 2012 Nov 19;209(12):2183-98. doi: 10.1084/jem.20120833. Epub 2012 Oct 22.

50.

Structure and conformation studies from temperature dependent infrared spectra of xenon solutions and ab initio calculations of cyclobutylgermane.

Guirgis GA, Klaassen JJ, Deodhar BS, Sawant DK, Panikar SS, Dukes HW, Wyatt JK, Durig JR.

Spectrochim Acta A Mol Biomol Spectrosc. 2012 Dec;99:266-78. doi: 10.1016/j.saa.2012.09.038. Epub 2012 Sep 26.

PMID:
23085284

Supplemental Content

Support Center